The Potential of DM199 to Treat Preeclampsia
Current Treatment Options for Preeclampsia
Preeclampsia is the second leading cause of maternal death worldwide1, affecting an estimated 5 - 8% of all pregnancies. In the United States alone, approximately 50,000 severe cases are reported each year. Globally, preeclampsia and related hypertensive disorders contribute to the deaths of about 76,000 pregnant women and 500,000 babies each year.2 Research indicates that over 90% of these fatalities occur in low- and middle-income nations, underscoring the disproportionate impact of preeclampsia on minority communities.3
Currently, there are no FDA-approved treatment options to slow the disease progression of preeclampsia. In the absence of a standardized treatment, care typically involves close monitoring of the mother and, if serious complications develop, early delivery of the baby – regardless of gestational age. Medications like angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are contraindicated in preeclampsia because they have a small molecular size and can cross the placental barrier and negatively impact fetal development. A treatment that safely manages blood pressure and protects against vascular damage would represent a major and potentially life-saving breakthrough.
1. Force UPST. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. JAMA 2017; 317(16): 1661-7.
2. Preeclampsia - preeclampsia and maternal mortality: A global burden. Preeclampsia Foundation - Saving mothers and babies from preeclampsia.
3. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014; 2(6): e323-33.
